Journal ArticleClin Gastroenterol Hepatol · April 2021
Comparison data regarding anti-tumor necrosis factor drug concentrations in inflammatory bowel disease (IBD) between the enzyme-linked immunosorbent assay (ELISA) and the homogenous mobility shift assay (HMSA) are scarce.1-3 As decisions in clinical practi ...
Full textLink to itemCite
Journal ArticleJ Clin Med · September 2, 2020
An upward drift for both infliximab and adalimumab concentrations measured by the homogenous mobility shift assay (HMSA) was previously reported. We aimed to investigate the impact of this drift on clinical care of patients with inflammatory bowel disease. ...
Full textLink to itemCite
Journal ArticleJ Viral Hepat · October 2019
We have previously shown that ultrasound identifies significant steatosis in patients with chronic HBV (CHB). However, the relationship between CHB, metabolic syndrome (MS) and steatosis is poorly understood. In this tertiary care, single-centre retrospect ...
Full textLink to itemCite
Journal ArticleWorld J Gastroenterol · August 14, 2019
Patients with long-standing inflammatory bowel disease (IBD) involving at least 1/3 of the colon are at increased risk for colorectal cancer (CRC). Advancements in CRC screening and surveillance and improved treatment of IBD has reduced CRC incidence in pa ...
Full textLink to itemCite
Journal ArticleCurr Opin Gastroenterol · July 2018
PURPOSE OF REVIEW: This review article will discuss the risk of colorectal cancer (CRC) in patients with inflammatory bowel disease (IBD), as well as the current recommendations for CRC screening and surveillance in patients with ulcerative colitis or Croh ...
Full textLink to itemCite
Journal ArticleClin Immunol · June 2018
Anti-TNF agents are widely used to treat immune-mediated disorders. Reactivation of Hepatitis B virus (HBV) is associated with immunosuppressive agents and biologics such as anti-TNF. There are limited data and differing guidelines for patients with negati ...
Full textLink to itemCite
Journal ArticleJ Cell Sci · August 1, 2010
Syncoilin is an atypical type III intermediate filament (IF) protein, which is expressed in muscle and is associated with the dystrophin-associated protein complex. Here, we show that syncoilin is expressed in both the central and peripheral nervous system ...
Full textLink to itemCite
Journal ArticleJ Struct Biol · March 2009
Syncoilin is a 64kDa intermediate filament (IF) protein expressed in myocytes at the sarcolemma, perinucleus, myotendenous and neuromuscular junctions. Here we present a revised domain projection and structural analysis for the original isoform (sync-1) an ...
Full textLink to itemCite
Journal ArticleCell Motil Cytoskeleton · June 2007
We previously described the Trypanin family of cytoskeleton-associated proteins that have been implicated in dynein regulation [Hill et al., J Biol Chem2000; 275(50):39369-39378; Hutchings et al., J Cell Biol2002;156(5):867-877; Rupp and Porter, J Cell Bio ...
Full textLink to itemCite